Clinical Trial

PHP and Immunotherapy in Metastasized UM

Study acronym: CHOPIN
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Melanoma of the eye (ocular/uveal melanoma) is an uncommon type of cancer that is associated with a high mortality. It usually disseminates rapidly throughout the body, most commonly to the liver and lungs. In this study a combination therapy with immunotherapy (ipilimumab with nivolumab) and chemotherapy (melphalan) will be assessed for the treatment of disseminated uveal melanoma. Melphalan will be administered selectively to the liver via percutaneous hepatic perfusion, limiting the systemic effect of chemotherapy. With this treatment combination we aim to find a treatment for disseminated uveal melanoma, both in the liver as in the other organs.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2020-02-21; most recent amendment 2025-09-02.
Status change: Recruiting → Active, Not Recruiting 2025-06-24
Trial Details
NCT Number NCT04283890
Lead Sponsor Leiden University Medical Center
Conditions Uveal Melanoma, Metastatic
Enrollment 83 participants
Start Date 2019-12-04
Primary Completion 2026-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2025-09-09